Leveraging large-scale multi-omics evidences to identify therapeutic targets from genome-wide association studies
Combining variant annotation, activity-by-contact maps, and molQTL increases performance to identify causal genes, while informing on directionality which can be translated to successful target identification and drug development.
Authors
- Khader Shameer (ORCID: https://orcid.org/0000-0002-9982-1911)
- Samuel Lessard (ORCID: https://orcid.org/0000-0002-1010-2268)
- Deepak K. Rajpal (ORCID: https://orcid.org/0000-0001-9289-6366)
- Kadri Reis (ORCID: https://orcid.org/0000-0002-2144-5856)
- Priit Palta (ORCID: https://orcid.org/0000-0001-9320-7008)
- Emanuele de Rinaldis (ORCID: https://orcid.org/0000-0002-0221-1114)
- Mathieu Beauvais
- Jennifer Sloane
- Clément Chatelain (ORCID: https://orcid.org/0000-0001-7265-6410)
- Michael J. Chao
- K. Klinger
Institutions
- Sanofi (France) (FR)
- AVEO Oncology (United States) (US)
- Sanofi (United States) (US)
- University of Tartu (EE)
Publication Details
- Journal
- BMC Genomics
- Published
- 2024-11-19
- DOI
- https://doi.org/10.1186/s12864-024-10971-2
- Citations
- 11
- Primary Topic
- Genetic Associations and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 6.05
Funders
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Novartis
- Sanofi
- Biogen
- Celgene
- AbbVie
- Wellcome Trust
- Maze Therapeutics
- Cancer Research UK
- British Heart Foundation
- European Commission
- Eesti Teadusagentuur
- Northwest Regional Development Agency
- Business Finland
- European Research Area Network on Cardiovascular Diseases
- Genentech
- Medical Research Council
- Estonian Research Competency Council
- Horizon 2020
- European Regional Development Fund
- Janssen Biotech